Seattle genetics announces positive tucatinib her2climb trial results

Seattle genetics announces positive tucatinib her2climb trial results in locally advanced or metastatic her2-positive breast cancer.seattle genetics inc - tucatinib her2climb's nda and maa on track for submission by q1 of 2020.

SGEN Ratings Summary

SGEN Quant Ranking